Clinical Attribute – Page 3

Novartis Intensifies Entresto Defense with FDA Complaint Amid Patent Lawsuits

12 months ago talkbio0Tagged Complaint:Find:Pt:^Patient:Nom, Entresto, Novartis, United States Food and Drug Administration

Novartis, Entresto, FDA complaint, patent lawsuits, pharmaceuticals

FTC’s Proposed Noncompete Ban: A Game Changer for Biopharma Job Mobility

1 year ago talkbio0Tagged Balinese language, Biopharma, competition, Employee, Range of Motion, Articular, rights, Rules of conduct, United States Federal Trade Commission

FTC, Noncompete Ban, Biopharma Jobs, Job Mobility, Employee Rights, Competition Law

Director/Vice President of Translational Research: Leading the Bridge from Discovery to Clinical Development

1 year ago talkbio0Tagged approvals, Biological Assay, Biological Markers, Biomarker Strategy, Clinical Development, Clinical Trial Design, Cross-Functional Collaboration, development aspects, Discover, Drug Molecule Development, End Point, Leadership, PK/ PD/, Preclinical Development, regulatory, Target, Team Building, Translational Research, Biomedical, Translational Science Leadership

Translational Research, Biomarker Discovery, Preclinical Development, Early Clinical Development, Drug Molecule Development, Translational Science Leadership, Biomarker Development, Target Engagement Strategies, Assay Development (PK/ PD/ Immunogenicity), Clinical Trial Design, Endpoint and Biomarker Strategy, Team Building and Leadership, Cross-Functional Collaboration, Regulatory Approvals

FDA Greenlights Idorsia’s Aprocitentan (Tryvio) for Resistant Hypertension Patients

1 year ago talkbio0Tagged 12.5 mg, Approved, aprocitentan, aspects of adverse effects, Availability of, Clinical Trials, Combined Modality Therapy, Edema, Endothelin receptor antagonist, Idorsia, Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative, Liquid substance, Precision - temporal, Recommended dosage, Resistant hypertensive disorder, Retention (Psychology), Second Half of 2024, Tryvio, Uncontrolled hypertension, United States Food and Drug Administration

FDA approval, Idorsia, Aprocitentan, Tryvio, Resistant hypertension, Endothelin receptor antagonist, Systolic blood pressure, Uncontrolled hypertension, Combination therapy, Clinical trials, PRECISION study, Recommended dosage: 12.5 mg, Availability: Second half of 2024, Edema and fluid retention side effects

Roche and Alnylam’s Hypertension Hopeful Zilebesiran Shows Promising Results in Combination Therapy Trial

1 year ago talkbio0Tagged Alnylam, Angiotensinogen, Combined Modality Therapy, control of blood pressure, Hypertensive disease, Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative, RNA Interference, Roche (company), Safety, Zilebesiran

Roche, Alnylam, Zilebesiran, Hypertension, Combination Therapy, Phase 2 Trial, Blood Pressure Control, AngioTensinogen (AGT), RNA Interference (RNAi) Therapeutic, Significant Reductions in Systolic Blood Pressure, Encouraging Safety Profile